Updated September 20, 2026: This article has been updated to include comments from study co-lead Moran Amit and to clarify the distinction between the study’s peripheral and central mechanistic findings and what remains unproven in patients.
More than half of patients getting platinum-based chemotherapy develop lasting nerve damage from the treatment itself, pain, numbness, burning, and heightened sensitivity to cold that can persist for years. It’s common enough, and severe enough, that it regularly forces oncologists to cut chemotherapy doses or stop treatment early, even when the cancer is still responding. There’s never been an effective way to prevent it. A study published September 3 in Science, led by researchers at MD Anderson Cancer Center, found that two doses of psilocybin, given just before chemotherapy starts, stopped this nerve damage from developing at all in mice, and the protection lasted through six full treatment cycles.
What breaks in the nerves, and what psilocybin fixes
Chemotherapy drugs like cisplatin damage nerve cells by depleting their mitochondria, the small structures that generate a cell’s energy, specifically in the long, thin extensions of the nerve that reach out to the skin. Without enough mitochondria able to travel to where the energy is needed, those nerve endings start to fail. The MD Anderson team, co-led by Moran Amit and Patrick Dougherty, found that psilocybin doesn’t restore how much total energy the mitochondria can produce. Instead, it keeps the mitochondria moving and properly positioned within the nerve fiber, so the energy being made reaches the parts of the cell that need it. In mice, that was enough: two doses of psilocybin, given nine days and two days before the first chemotherapy session, completely prevented the animals from developing pain and cold sensitivity, and the effect held up through six separate rounds of chemotherapy.
The finding wasn’t what the lab set out to test, and its own discoverers needed convincing. Moran Amit, a head and neck surgeon in MD Anderson’s Cancer Neuroscience Program who co-led the study, said his first reaction was skepticism, “given the lack of success with other therapeutics for neuropathy.” He said it took his team months to convince themselves the finding was real, arriving at confidence that the effect was, in his words, “reproducible and durable,” before the lab trusted the result enough to build on it.
Why this isn’t just another version of psilocybin’s psychiatric mechanism
Almost everything written about psilocybin’s therapeutic potential, cancer-related distress and pain conditions like fibromyalgia included, traces back to its effects on serotonin signaling in the brain, either recalibrating central pain processing or reducing the psychological distress that makes pain feel worse. This finding adds to that story instead of standing entirely apart from it. The mechanism the paper demonstrates for preventing nerve damage is peripheral: a serotonin receptor, 5-HT2A, acting locally at the nerve to preserve cellular transport machinery. The same paper also reports that psilocybin normalized medial prefrontal cortical synaptic activity and cortical alpha and beta EEG power in the treated animals, a central effect observed alongside the peripheral one. The study does not establish that the central change caused the neuropathy protection, and how much each mechanism, peripheral or central, contributes to the outcome researchers measured remains unresolved. What the peripheral finding does establish is a mechanism specific to nerve protection that doesn’t depend on whether the brain-based mechanisms behind psilocybin’s psychiatric effects hold up in larger trials. The same study observed both the peripheral and central effects in the same animals without establishing any causal relationship between them.
Amit’s own account of how this connects to his lab’s other work goes a step further than what the paper’s data alone establish. Asked whether he sees a relationship between the neuropathy mechanism and his team’s separate trials of psilocybin-assisted therapy for cancer-related anxiety and depression, which rely on that same brain-based mechanism, he said he believes shared central mechanisms contribute to the neuropathy-protective effect. The paper itself supports part of that: it reports that psilocybin normalized central cortical activity in the same animals that were protected from nerve damage. What it does not establish is that this central change is what contributed to the protection, rather than a separate effect of the drug that happened alongside it. Amit’s suggestion of a shared central contribution is an interpretation that the study’s observations neither establish nor rule out.
“There are shared central mechanisms that contribute to the beneficial effects we’re seeing in neuropathy.”
— Moran Amit
Why the human tissue confirmation matters more than the mouse data alone
Mouse studies of nerve protection often don’t translate to humans, a real limit worth taking seriously with any psychedelic finding built on animal models alone. This study went further than most: the researchers tested human donor sensory neurons and skin biopsies from real patients, and found the same serotonin receptor to mitochondrial-trafficking pathway present and functional in human tissue, not just mouse tissue. That doesn’t guarantee the drug will work the same way in a living patient going through chemotherapy, but it strengthens the case that the underlying biology is real and relevant to humans, not an artifact of the mouse model.
The detail that determines whether this could ever be used
A neuroprotective drug that also protects cancer cells from chemotherapy would be worse than useless. The study specifically tested this, and found psilocybin’s protection of healthy nerve tissue did not reduce chemotherapy’s ability to kill tumor cells in the same animals. That’s the single most important safety finding in the whole study for any real-world application, since it’s the one result that could have ended this idea immediately if it had gone the other way.
What happens next
These findings are already the basis for a registered Phase 2 trial, NeuroGuard, testing psilocybin given during chemotherapy across multiple cancer types, specifically to see whether what worked in mice and human tissue produces a measurable reduction in nerve damage in cancer patients. That trial hasn’t reported results yet. Asked what would worry him most as NeuroGuard moves into actual chemotherapy patients, Amit didn’t name a specific translation risk. He pointed instead to psilocybin’s existing safety record and MD Anderson’s broader trial experience with the drug in cancer patients as the basis for his confidence heading into the trial. Separately, the same research group is running trials testing psilocybin-assisted therapy for anxiety and depression in cancer patients, a distinct clinical application built primarily on that brain-based mechanism, meaning MD Anderson now has two separate psilocybin research programs running in the same patient population for two different clinical purposes. Whether the underlying biology behind those two programs is actually as separate as the indications themselves is, per the central-nervous-system findings above, an open question, not a settled one.
What this doesn’t prove yet
This is preclinical and translational research, mouse models and human tissue samples, not a clinical trial in actual chemotherapy patients. Nothing here confirms psilocybin prevents neuropathy in a real cancer patient, only that the mechanism appears to exist and appears to translate to human cells. The specific dosing schedule used in mice, timed doses before chemotherapy begins, may or may not be the right approach in humans, and how psilocybin’s well-known perceptual effects would be managed in patients undergoing cancer treatment, rather than a dedicated psychiatric session, remains an open practical question the Phase 2 trial will need to address directly.